UAE Becomes First Country to Approve Oral Treatment for Non-Segmental Vitiligo

The UAE has become the first country in the world to approve an oral treatment for non-segmental vitiligo, giving eligible patients aged 12 and above a new systemic treatment option.

The Emirates Drug Establishment (EDE) has approved a new therapeutic indication for RINVOQ (upadacitinib) for adults and adolescents aged 12 years and older with non-segmental vitiligo whose condition requires systemic therapy.

The once-daily medicine is now licensed for eligible patients in the UAE under the approved medical criteria.

New treatment option for vitiligo patients

Vitiligo is a skin condition in which areas of the skin lose pigmentation, resulting in white patches. It occurs when melanocytes, the cells responsible for producing melanin, are destroyed. Although the exact cause is not fully understood, autoimmune mechanisms are considered an important factor.

The condition is not contagious and can affect different areas of the body. Its appearance may be more noticeable in people with darker skin tones.

The UAE's latest approval is significant because it introduces an oral systemic treatment for eligible patients with non-segmental vitiligo, expanding the range of treatment options available to them.

What is non-segmental vitiligo?

Non-segmental vitiligo is the more common form of the condition and can affect multiple areas of the body. Treatment depends on factors including the extent and location of pigmentation loss and the patient's individual circumstances.

Existing treatment approaches may include topical medicines, phototherapy and certain laser-based treatments. Systemic therapy may be considered when a patient's condition meets appropriate medical criteria.

Not every white patch on the skin is caused by vitiligo, making professional assessment important before treatment begins.

UAE strengthens access to innovative medicines

The EDE said the approval reflects the UAE's regulatory capabilities and its efforts to respond to developments in medical science.

The authority said the move also supports the country's pharmaceutical sector and efforts to accelerate access to innovative treatments.

The approval allows eligible patients to have access to an oral therapy that can be taken once daily, subject to medical evaluation and the approved indication.

Patients advised to seek specialist assessment

The EDE has urged people who notice unusual changes in skin colour to consult a medical specialist.

Early assessment can help establish the correct diagnosis and allow healthcare professionals to determine the most appropriate treatment based on the individual's condition.

As with any prescription medicine, patients should discuss the potential benefits, risks, suitability and monitoring requirements of upadacitinib with their treating healthcare professional before starting treatment.